Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years and older. It also has anxiolytic properties.
## Primary Indications
* Adjunctive therapy for seizures in Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week, as tolerated, up to a maximum of 20 mg twice daily.
* **Maintenance:** Doses are typically given twice daily, but a once-daily evening dose may be considered for maintenance.
## Pediatric Dosing (2 years and older)
* **Initiation:** 2.5 mg twice daily.
* **Titration:** Increase dose by 2.5 mg to 5 mg every week, as tolerated, up to a maximum daily dose of 0.5 mg/kg/day divided into two doses.
* **Maximum:** Do not exceed the adult maximum dose of 20 mg twice daily, even if the calculated pediatric dose is higher.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Dose reduction may be necessary.
* **Renal Impairment:** Use with caution. Dose reduction may be necessary.
* **Concomitant Medications:** Consider reduced clobazam dosage when used with strong CYP3A4 inhibitors or CYP2C19 inhibitors.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic insufficiency.
* Acute narrow-angle glaucoma.
## Adverse Effects
* **Common:** Somnolence, constipation, decreased appetite, fatigue, irritability, aggression, mood changes, upper respiratory tract infection, gait disturbance, ataxia, cough, vomiting, diarrhea, rash.
* **Serious:** Severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior or ideation, respiratory depression, dependence and withdrawal symptoms, cognitive and psychomotor impairment, paradoxical reactions.
## Key Drug Interactions
* **CYP2C19 Substrates (e.g., phenytoin, omeprazole):** Clobazam is a moderate inhibitor of CYP2C19; coadministration may increase concentrations of these drugs. Dose adjustments of the CYP2C19 substrate may be needed.
* **CYP3A4 Substrates:** Clobazam is metabolized by CYP3A4 and can induce or inhibit it.
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Additive CNS depressant effects may occur, leading to increased sedation, respiratory depression, and potentially fatal outcomes.
## Monitoring
* Monitor for signs of somnolence, fatigue, and decreased appetite.
* Monitor for behavioral changes, including suicidal ideation or depression.
* Monitor for signs of respiratory depression, especially when used with other CNS depressants.
* Monitor for signs of dependence and withdrawal upon discontinuation.
* Regularly assess seizure frequency and severity.
## Clinical Pearls
* Clobazam should be used as adjunctive therapy and not as monotherapy for LGS.
* Slow titration is recommended to minimize adverse effects.
* Abrupt discontinuation can lead to withdrawal symptoms; gradual tapering is advised.
* Patients and caregivers should be educated about the risks of suicidal behavior and CNS depression.
* Use caution when driving or operating machinery due to potential for drowsiness and impaired coordination.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and local protocols before making any clinical decisions.
